| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.13(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.56 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.3 |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
3 |
| Total Shares Sold |
0 |
294,129 |
382,411 |
1,047,483 |
| Total Sell Value |
$0 |
$4,424,082 |
$5,332,221 |
$12,970,668 |
| Total People Sold |
0 |
6 |
6 |
9 |
| Total Sell Transactions |
0 |
7 |
13 |
48 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Consylman Gina |
Chief Financial Officer |
• – – |
2018-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
85,907 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2018-02-21 |
4 |
AS |
$14.66 |
$52,688 |
D/D |
(3,594) |
55,907 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-01-24 |
4 |
AS |
$15.45 |
$927,000 |
D/D |
(60,000) |
775,000 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2018-01-24 |
4 |
OE |
$3.76 |
$225,600 |
D/D |
60,000 |
835,000 |
|
- |
|
| Consylman Gina |
Chief Financial Officer |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
59,501 |
|
- |
|
| Huyett William |
Chief Operating Officer |
• – – |
2018-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,250 |
56,250 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2017-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
159 |
60,635 |
|
- |
|
| Currie Mark G |
Chief Scientific Officer |
• – – |
2017-12-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500 |
19,758 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2017-12-07 |
4 |
S |
$15.00 |
$861,075 |
D/D |
(57,405) |
4,696,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2017-12-07 |
4 |
OE |
$3.76 |
$215,843 |
D/D |
57,405 |
4,754,322 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2017-12-06 |
4 |
S |
$15.24 |
$853,440 |
D/D |
(56,000) |
4,696,917 |
|
- |
|
| Hecht Peter M |
Chief Executive Officer |
• • – |
2017-12-06 |
4 |
OE |
$3.76 |
$310,557 |
D/D |
82,595 |
4,752,917 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2017-12-04 |
4 |
AS |
$16.45 |
$24,675 |
D/D |
(1,500) |
79,408 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2017-12-04 |
4 |
AS |
$16.09 |
$32,921 |
D/D |
(2,000) |
31,330 |
|
- |
|
| Consylman Gina |
Interim CFO and CAO |
• – – |
2017-11-10 |
4 |
AS |
$15.20 |
$13,133 |
D/D |
(864) |
52,001 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2017-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
153 |
60,476 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2017-09-05 |
4 |
AS |
$16.15 |
$32,300 |
D/D |
(2,000) |
33,330 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2017-09-05 |
4 |
AS |
$16.16 |
$24,240 |
D/D |
(1,500) |
80,908 |
|
- |
|
| Consylman Gina |
Chief Accounting Officer |
• – – |
2017-08-18 |
4 |
AS |
$14.34 |
$2,968 |
D/D |
(207) |
52,865 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2017-06-22 |
4 |
AS |
$19.75 |
$691,250 |
D/D |
(35,000) |
0 |
|
- |
|
| Gilbert Halley E |
Chief Legal Officer |
• – – |
2017-06-22 |
4 |
OE |
$3.76 |
$131,600 |
D/D |
35,000 |
35,000 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
142 |
60,323 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2017-06-08 |
4 |
AS |
$17.78 |
$56,896 |
D/D |
(3,200) |
35,330 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
60,181 |
|
- |
|
| Williams Douglas E |
Director |
– • – |
2017-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,625 |
75,633 |
|
- |
|
584 Records found
|
|
Page 16 of 24 |
|
|
0.16 (2.41%) 
